High-Throughput Molecular and Histopathologic Profiling of Tumor Tissue in a Novel Transplantable Model of Murine Neuroblastoma: New Tools for Pediatric Drug Discovery

REFERENCES

• Brodeur GM, Maris JM. Neuroblastoma. In Principles and Practice of Pediatric Oncology, PA Pizzo and DG Poplack (eds.). Philadelphia, PA: Lippincott William & Wilkins, 2002:895–938.
   Google Scholar
• Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203–216.
   PubMed Web of Science ®Google Scholar
• Goldsby RE, Matthay KK. Neuroblastoma: evolving therapies for a disease with many faces. Paediatr Drugs 2004;6:107–122.
   PubMedGoogle Scholar
• Weinstein JL, Katzenstein HM, Cohn SL. Advances in the diagnosis and treatment of neuroblastoma. Oncologist 2003;8:278–292.
   PubMed Web of Science ®Google Scholar
• Wigginton J. Preclinical animal models for the investigation of biologic approaches for the therapy of neuroblastoma. In Renal and Adrenal Tumors: Biology and Management, A Belldegrun, R Figlin, D Vaughn, A Ritchie, and T Oliver (eds.). New York: Oxford University Press, 2003, 144–155.
   Google Scholar
• Lode HN, Dreier T, Xiang R, Varki NM, Kang AS, Reisfeld RA. Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma. Proc Natl Acad Sci U S A 1998;95:2475–2480.
   PubMed Web of Science ®Google Scholar
• Lode HN, Xiang R, Varki NM, Dolman CS, Gillies SD, Reisfeld RA. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer Inst 1997;89:1586–1594.
   PubMed Web of Science ®Google Scholar
• Katsanis E, Blazar BR, Bausero MA, Gunther R, Anderson PM. Retroperitoneal inoculation of murine neuroblastoma results in a reliable model for evaluation of the antitumor immune response. J Pediatr Surg 1994;29:538–542.
   PubMed Web of Science ®Google Scholar
• Katsanis E, Bausero MA, Panoskaltsis-Mortari A, Dancisak BB, Xu Z, Orchard PJ, Davis CG, Blazar BR. Irradiation of singly and doubly transduced murine neuroblastoma cells expressing B7-1 and producing interferon-gamma reduces their capacity to induce systemic immunity. Cancer Gene Ther 1996;3:75–82.
   PubMed Web of Science ®Google Scholar
• Fowler C, Zimmer C, Boghaert E, Thomas M, Zimmer S. Metastasis of C1300 and TBJ murine neuroblastomas correlates with expression of matrix metalloproteinases. Cancer Lett 1995;93:171–177.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Berhanu A, Redlinger RE, Jr., Watkins S, Lotze MT, Barksdale EM, Jr. Interleukin-12 transduced dendritic cells induce regression of established murine neuroblastoma. J Pediatr Surg 2001;36:1285–1292.
   PubMed Web of Science ®Google Scholar
• Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121–1124.
   PubMed Web of Science ®Google Scholar
• Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111–1116.
   PubMed Web of Science ®Google Scholar
• Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997;16:2985–2995.
   PubMed Web of Science ®Google Scholar
• Okabe M, Ikawa M, Kominami K, Nakanishi T, Nishimune Y. “Green mice” as a source of ubiquitous green cells. FEBS Lett 1997;407:313–319.
   PubMed Web of Science ®Google Scholar
• Khan T, Hixon JA, Stauffer JK, Lincoln E, Back TC, Brenner J, Lockett S, Nagashima K, Powell D, Wigginton JM. Therapeutic modulation of Akt activity and antitumor efficacy of interleukin-12 against orthotopic murine neuroblastoma. J Natl Cancer Inst 2006;98:190–202.
   PubMed Web of Science ®Google Scholar
• Salcedo R, Stauffer JK, Lincoln E, Back TC, Hixon JA, Hahn C, Shafer-Weaver K, Malyguine A, Kastelein R, Wigginton JM. IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells. J Immunol 2004;173:7170–7182.
   PubMed Web of Science ®Google Scholar
• Motoike T, Loughna S, Perens E, Roman BL, Liao W, Chau TC, Richardson CD, Kawate T, Kuno J, Weinstein BM, Stainier DY, Sato TN. Universal GFP reporter for the study of vascular development. Genesis 2000;28:75–81.
   PubMed Web of Science ®Google Scholar
• Eisenhofer G, Goldstein DS, Stull R, Keiser HR, Sunderland T, Murphy DL, Kopin IJ. Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clin Chem 1986;32:2030–2033.
   PubMed Web of Science ®Google Scholar
• Stauffer JK, Khan T, Salcedo R, Hixon JA, Lincoln E, Back TC, Wigginton JM. Multicolor fluorescence-based approaches for imaging cytokine-induced alterations in the neovascularization, growth, metastasis, and apoptosis of murine neuroblastoma tumors. J Immunother 2006;29:151–164.
   PubMed Web of Science ®Google Scholar
• Wigginton JM, Gruys E, Geiselhart L, Subleski J, Komschlies KL, Park JW, Wiltrout TA, Nagashima K, Back TC, Wiltrout RH. IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest 2001;108:51–62.
   PubMed Web of Science ®Google Scholar
• Wei J, Khan J. Purification of total RNA from mammalian cells and tissues. In DNA Microarays: A Molecular Cloning Manual, D Botwell and J Sambrook (eds.). Cold Spring Harbor, NY: Cold Spring Harbor Press, 2002, 110–119.
   Google Scholar
• Sotiriou C, Khanna C, Jazaeri AA, Petersen D, Liu ET. Core biopsies can be used to distinguish differences in expression profiling by cDNA microarrays. J Mol Diagn 2002;4:30–36.
   PubMed Web of Science ®Google Scholar
• Hegde P, Qi R, Abernathy K, Gay C, Dharap S, Gaspard R, Hughes JE, Snesrud E, Lee N, Quackenbush J. A concise guide to cDNA microarray analysis. Biotechniques 2000;29:548–550; 52–54, 56 passim.
   PubMed Web of Science ®Google Scholar
• Wei JS, Greer BT, Westermann F, Steinberg SM, Son CG, Chen QR, Whiteford CC, Bilke S, Krasnoselsky AL, Cenacchi, N, Catchpoole D, Berthold F, Schwab M, Khan J. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res 2004;64:6883–6891.
   PubMed Web of Science ®Google Scholar
• Krasnoselsky AL, Whiteford CC, Wei JS, Bilke S, Westermann F, Chen QR, Khan J. Altered expression of cell cycle genes distinguishes aggressive neuroblastoma. Oncogene 2005;24:1533–1541.
   PubMed Web of Science ®Google Scholar
• Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116–5121.
   PubMed Web of Science ®Google Scholar
• Meitar D, Crawford SE, Rademaker AW, Cohn SL. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 1996;14:405–414.
   PubMed Web of Science ®Google Scholar
• Stickler GB, Flock EV. Neuroblastoma and ganglioneuroblastoma: associated increased urinary excretion of catecholamines. Cancer Chemother Rep 1962;16:439–442.
   PubMedGoogle Scholar
• Voorhess ML, Gardner LI. The value of serial catecholamine determinations in children with neuroblastoma. Pediatrics 1962;30:241–246.
   PubMed Web of Science ®Google Scholar
• Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165–1173.
   PubMed Web of Science ®Google Scholar
• Gilman AL, Ozkaynak MF, Matthay KK, Krailo M, Yu AL, Gan J, Sternberg A, Hank JA, Reaman GH, Sondel PM. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group. J Clin Oncol 2009;27:85–91.
   PubMed Web of Science ®Google Scholar
• Shimada H, Umehara S, Monobe Y, Hachitanda Y, Nakagawa A, Goto S, Gerbing RB, Stram DO, Lukens JM, Mathtay KK. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 2001;92:2451–2461.
   PubMed Web of Science ®Google Scholar
• Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer 1999;86:349–363.
   PubMed Web of Science ®Google Scholar
• LaBrosse EH, Comoy E, Bohuon C, Zucker JM, Schweisguth O. Catecholamine metabolism in neuroblastoma. J Natl Cancer Inst 1976;57:633–638.
   PubMed Web of Science ®Google Scholar
• Pritchard J, Barnes J, Germond S, Hartman O, de Kraker J, Lewis I, Lockwood L, Wallendszus K. Stage and urinary catecholamine metabolite excretion in neuroblastoma. European Neuroblastoma Study Group. Lancet 1989;2:514–515.
   PubMed Web of Science ®Google Scholar
• Ribatti D, Ponzoni M. Antiangiogenic strategies in neuroblastoma. Cancer Treat Rev 2005;31:27–34.
   PubMed Web of Science ®Google Scholar
• Shusterman S, Maris JM. Prospects for therapeutic inhibition of neuroblastoma angiogenesis. Cancer Lett 2005;228:171–179.
   PubMed Web of Science ®Google Scholar
• Streck CJ, Ng CY, Zhang Y, Zhou J, Nathwani AC, Davidoff AM. Interferon-mediated anti-angiogenic therapy for neuroblastoma. Cancer Lett 2005;228:163–170.
   PubMed Web of Science ®Google Scholar
• Wang B, Xiao Y, Ding BB, Zhang N, Yuan X, Gui L, Qian KX, Duan S, Chen Z, Rao Y, Geng JG. Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity. Cancer Cell 2003;4:19–29.
   PubMed Web of Science ®Google Scholar
• Wong K, Park HT, Wu JY, Rao Y. Slit proteins: molecular guidance cues for cells ranging from neurons to leukocytes. Curr Opin Genet Dev 2002;12:583–591.
   PubMed Web of Science ®Google Scholar
• Wang KH, Brose K, Arnott D, Kidd T, Goodman CS, Henzel W, Tessier-Lavigne M. Biochemical purification of a mammalian slit protein as a positive regulator of sensory axon elongation and branching. Cell 1999;96:771–784.
   PubMed Web of Science ®Google Scholar
• Wu W, Wong K, Chen J, Jiang Z, Dupuis S, Wu JY, Rao Y. Directional guidance of neuronal migration in the olfactory system by the protein Slit. Nature 1999;400:331–336.
   PubMed Web of Science ®Google Scholar
• Gao AG, Lindberg FP, Finn MB, Blystone SD, Brown EJ, Frazier WA. Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin. J Biol Chem 1996;271:21–24.
   PubMed Web of Science ®Google Scholar
• Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A 1990;87:6624–6628.
   PubMed Web of Science ®Google Scholar
• Yang QW, Liu S, Tian Y, Salwen HR, Chlenski A, Weinstein J, Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma. Cancer Res 2003;63:6299–6310.
   PubMed Web of Science ®Google Scholar
• Castle VP, Ou X, O'Shea S, Dixit VM. Induction of thrombospondin 1 by retinoic acid is important during differentiation of neuroblastoma cells. J Clin Invest 1992;90:1857–1863.
   PubMed Web of Science ®Google Scholar
• Miyashita M, Ohnishi H, Okazawa H, Tomonaga H, Hayashi A, Fujimoto TT, Furuya N, Matozaki T. Promotion of neurite and filopodium formation by CD47: roles of integrins, Rac, and Cdc42. Mol Biol Cell 2004;15:3950–3963.
   PubMed Web of Science ®Google Scholar
• Handsley MM, Edwards DR. Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer 2005;115:849–860.
   PubMed Web of Science ®Google Scholar
• Stetler-Stevenson WG, Seo DW. TIMP-2: an endogenous inhibitor of angiogenesis. Trends Mol Med 2005;11:97–103.
   PubMed Web of Science ®Google Scholar
• Ara T, Fukuzawa M, Kusafuka T, Komoto Y, Oue T, Inoue M, Okada A. Immunohistochemical expression of MMP-2, MMP-9, and TIMP-2 in neuroblastoma: association with tumor progression and clinical outcome. J Pediatr Surg 1998;33:1272–1278.
   PubMed Web of Science ®Google Scholar
• Spurbeck WW, Ng CY, Strom TS, Vanin EF, Davidoff AM. Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model. Blood 2002;100: 3361–3368.
   PubMed Web of Science ®Google Scholar
• Spurbeck WW, Ng CY, Vanin EF, Davidoff AM. Retroviral vector-producer cell-mediated in vivo gene transfer of TIMP-3 restricts angiogenesis and neuroblastoma growth in mice. Cancer Gene Ther 2003;10:161–167.
   PubMed Web of Science ®Google Scholar
• Iolascon A, Borriello A, Giordani L, Cucciolla V, Moretti A, Monno F, Criniti V, Marzullo A, Criscuolo M, Garione FD. Caspase 3 and 8 deficiency in human neuroblastoma. Cancer Genet Cytogenet 2003;146:41–47.
   PubMed Web of Science ®Google Scholar
• Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Lahti JM, Kidd VJ. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000;6:529–535.
   PubMed Web of Science ®Google Scholar
• Koizumi H, Ohkawa I, Tsukahara T, Momoi T, Nakada K, Uchikoshi T. Apoptosis in favourable neuroblastomas is not dependent on Fas (CD95/APO-1) expression but on activated caspase 3 (CPP32). J Pathol 1999;189:410–415.
   PubMed Web of Science ®Google Scholar
• Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 1998;351:882–883.
   PubMed Web of Science ®Google Scholar
• Islam A, Kageyama H, Takada N, Kawamoto T, Takayasu H, Isogai E, Ohira M, Hashizume K, Kobayashi H, Kaneko Y, Nakagawara A. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000;19:617–623.
   PubMed Web of Science ®Google Scholar
• van Golen CM, Castle VP, Feldman EL. IGF-I receptor activation and BCL-2 overexpression prevent early apoptotic events in human neuroblastoma. Cell Death Differ 2000;7:654–665.
   PubMed Web of Science ®Google Scholar
• Poulaki V, Mitsiades N, Romero ME, Tsokos M. Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and Bcl-2. Cancer Res 2001;61:4864–4872.
   PubMed Web of Science ®Google Scholar
• Ho R, Eggert A, Hishiki T, Minturn JE, Ikegaki N, Foster P, Camoratto AM, Evans AE, Brodeur GM. Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res 2002;62:6462–6466.
   PubMed Web of Science ®Google Scholar
• Kim S, Kang J, Hu W, Evers BM, Chung DH. Geldanamycin decreases Raf-1 and Akt levels and induces apoptosis in neuroblastomas. Int J Cancer 2003;103:352–359.
   PubMed Web of Science ®Google Scholar
• Kim S, Kang J, Qiao J, Thomas RP, Evers BM, Chung DH. Phosphatidylinositol 3-kinase inhibition down-regulates survivin and facilitates TRAIL-mediated apoptosis in neuroblastomas. J Pediatr Surg 2004;39:516–521.
   PubMed Web of Science ®Google Scholar
• Shankar SL, Mani S, O'Guin KN, Kandimalla ER, Agrawal S, Shafit-Zagardo B. Survivin inhibition induces human neural tumor cell death through caspase-independent and -dependent pathways. J Neurochem 2001;79:426–436.
   PubMed Web of Science ®Google Scholar
• Bown N, Lastowska M, Cotterill S, O'Neill S, Ellershaw C, Roberts P, Lewis I, Pearson AD. 17q gain in neuroblastoma predicts adverse clinical outcome. U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group. Med Pediatr Oncol 2001;36:14–19.
   PubMedGoogle Scholar
• Lastowska M, Cotterill S, Bown N, Cullinane C, Variend S, Lunec J, Strachan T, Pearson AD, Lackson MS. Breakpoint position on 17q identifies the most aggressive neuroblastoma tumors. Genes Chromosomes Cancer 2002;34:428–436.
   PubMed Web of Science ®Google Scholar
• Pratt MA, Niu M, White D. Differential regulation of protein expression, growth and apoptosis by natural and synthetic retinoids. J Cell Biochem 2003;90:692–708.
   PubMed Web of Science ®Google Scholar
• Goldsmith KC, Hogarty MD. Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma. Cancer Lett 2005;228:133–141.
   PubMed Web of Science ®Google Scholar
• Zaffaroni N, Pennati M, Daidone MG. Survivin as a target for new anticancer interventions. J Cell Mol Med 2005;9:360–372.
   PubMed Web of Science ®Google Scholar
• Emanuel S, Rugg CA, Gruninger RH, Lin R, Fuentes-Pesquera A, Connolly PJ, Wetter SK, Hollister B, Kruger WW, Napier C, Jolliffe, Middleton SA. The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. Cancer Res 2005;65:9038–9046.
   PubMed Web of Science ®Google Scholar
• Young MA, Shah NP, Chao LH, Seeliger M, Milanov ZV, Biggs WH, 3rd, Treiber DK, Patel HK, Zarrinkar PP, Lockart DJ, Sawyers CL, Kuriyan J. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 2006;66:1007–1014.
   PubMed Web of Science ®Google Scholar
• Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Mloney A, Raynaud F, Campbell M, Walton M, Lakhani, Kaye S, Workman P, Judson I. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23:4152–4161.
   PubMed Web of Science ®Google Scholar
• Xiao HH, Makeyev Y, Butler J, Vikram B, Franklin WA. 7-Hydroxystaurosporine (UCN-01) preferentially sensitizes cells with a disrupted TP53 to gamma radiation in lung cancer cell lines. Radiat Res 2002;158:84–93.
   PubMed Web of Science ®Google Scholar
• Eckerdt F, Yuan J, Strebhardt K. Polo-like kinases and oncogenesis. Oncogene 2005;24:267–276.
   PubMed Web of Science ®Google Scholar
• Gumireddy K, Reddy MV, Cosenza SC, Boominathan R, Baker SJ, Papathi N, Jiang J, Holland J, Reddy EP. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 2005;7:275–286.
   PubMed Web of Science ®Google Scholar
• Shapiro GI. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res 2004;10:4270s–4275s.
   PubMed Web of Science ®Google Scholar
• Swanton C. Cell-cycle targeted therapies. Lancet Oncol 2004; 5:27–36.
   PubMed Web of Science ®Google Scholar
• Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, Barrett JC. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 1995;268:884–886.
   PubMed Web of Science ®Google Scholar
• Cowin P, Rowlands TM, Hatsell SJ. Cadherins and catenins in breast cancer. Curr Opin Cell Biol 2005;17:499–508.
   PubMed Web of Science ®Google Scholar
• Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004;303:1483–1487.
   PubMed Web of Science ®Google Scholar
• Wheelock MJ, Johnson KR. Cadherins as modulators of cellular phenotype. Annu Rev Cell Dev Biol 2003;19:207–235.
   PubMed Web of Science ®Google Scholar
• Reed CC, Waterhouse A, Kirby S, Kay P, Owens RT, McQuillan DJ, Iozzo RV. Decorin prevents metastatic spreading of breast cancer. Oncogene 2005;24:1104–1110.
   PubMed Web of Science ®Google Scholar
• Ikeyama S, Koyama M, Yamaoko M, Sasada R, Miyake M. Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA. J Exp Med 1993;177:1231–1237.
   PubMed Web of Science ®Google Scholar
• Cox JL, Sexton PS, Green TJ, Darmani NA. Inhibition of B16 melanoma metastasis by overexpression of the cysteine proteinase inhibitor cystatin C. Melanoma Res 1999;9:369–374.
   PubMed Web of Science ®Google Scholar
• Aryee DN, Ambros I, Ambros PF, Muehlbacher K, Luegmayr A, Yoshie O, Kovar H Frequent low level expression in Ewing sarcoma family tumors and widespread absence of the metastasis suppressor KAI1/CD82 in neuroblastoma. Pediatr Res 2002;52: 279–285.
   PubMed Web of Science ®Google Scholar
• Fazili Z, Sun W, Mittelstaedt S, Cohen C, Xu XX. Disabled-2 inactivation is an early step in ovarian tumorigenicity. Oncogene 1999;18:3104–3113.
   PubMed Web of Science ®Google Scholar
• Hsieh SY, Hsieh PS, Chiu CT, Chen WY. Dickkopf-3/REIC functions as a suppressor gene of tumor growth. Oncogene 2004;23:9183–9189.
   PubMed Web of Science ®Google Scholar
• Dang DT, Chen X, Feng J, Torbenson M, Dang LH, Yang VW. Overexpression of Kruppel-like factor 4 in the human colon cancer cell line RKO leads to reduced tumorigenecity. Oncogene 2003;22:3424–3430.
   PubMed Web of Science ®Google Scholar
• Li Y, Pei J, Xia H, Ke H, Wang H, Tao W. Lats2, a putative tumor suppressor, inhibits G1/S transition. Oncogene 2003;22:4398–4405.
   PubMed Web of Science ®Google Scholar
• Deng Y, Yao L, Chau L, Ng SS, Peng Y, Liu X, Au WS, Wang J, Li F, Ji S, Han H, Lie X, Li Q, Kung HF, Leung SY, Lin MC. N-Myc downstream-regulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation. Int J Cancer 2003;106:342–347.
   PubMed Web of Science ®Google Scholar
• Rossi M, Sayan AE, Terrinoni A, Melino G, Knight RA. Mechanism of induction of apoptosis by p73 and its relevance to neuroblastoma biology. Ann N Y Acad Sci 2004;1028: 143–149.
   PubMed Web of Science ®Google Scholar
• Terrinoni A, Ranalli M, Cadot B, Leta A, Bagetta G, Vousden KH, Melino G. p73-alpha is capable of inducing scotin and ER stress. Oncogene 2004;23:3721–3725.
   PubMed Web of Science ®Google Scholar
• Karim R, Tse G, Putti T, Scolyer R, Lee S. The significance of the Wnt pathway in the pathology of human cancers. Pathology 2004;36:120–128.
   PubMed Web of Science ®Google Scholar
• Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 2004;5:691–701.
   PubMed Web of Science ®Google Scholar
• Blanc E, Roux GL, Benard J, Raguenez G. Low expression of Wnt-5a gene is associated with high-risk neuroblastoma. Oncogene 2005;24:1277–1283.
   PubMed Web of Science ®Google Scholar
• Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 1998;95:7556–7561.
   PubMed Web of Science ®Google Scholar
• Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 1994;153:1697–1706.
   PubMed Web of Science ®Google Scholar
• Wigginton JM, Lee JK, Wiltrout TA, Alvord WG, Hixon JA, Subleski J, Back TC, Wiltrout RH. Synergistic engagement of an ineffective endogenous anti-tumor immune response and induction of IFN-gamma and Fas-ligand-dependent tumor eradication by combined administration of IL-18 and IL-2. J Immunol 2002;169:4467–4474.
   PubMed Web of Science ®Google Scholar
• Hisada M, Kamiya S, Fujita K, Belladonna ML, Aoki T, Koyanagi Y, Mizugucho J, Yoshito T. Potent antitumor activity of interleukin-27. Cancer Res 2004;64:1152–1156.
   PubMed Web of Science ®Google Scholar
• Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004;75:163–189.
   PubMed Web of Science ®Google Scholar
• Takeda A, Hamano S, Yamanaka A, Hanada T, Ishibashi T, Mak TW, Yoshimura A, Yoshida H. Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J Immunol 2003;170:4886–4890.
   PubMed Web of Science ®Google Scholar
• Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, Pflanz S, Zhang R, Singh KP, Vega F, To W, Wagner J, O'Farrell AM, McClanahan T, Zurawski S, Hannum C, Gorman D, Rennick DM, Kastelein RA, de Wall Malefyt R, Moore KW. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002;168:5699–5708.
   PubMed Web of Science ®Google Scholar
• Watford WT, Hissong BD, Bream JH, Kanno Y, Muul L, O'Shea JJ. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev 2004;202:139–156.
   PubMed Web of Science ®Google Scholar
• Lampson LA, Fisher CA. Weak HLA and beta 2-microglobulin expression of neuronal cell lines can be modulated by interferon. Proc Natl Acad Sci U S A 1984;81:6476–6480.
   PubMed Web of Science ®Google Scholar
• Whelan JP, Chatten J, Lampson LA. HLA class I and beta 2-microglobulin expression in frozen and formaldehyde-fixed paraffin sections of neuroblastoma tumors. Cancer Res 1985;45:5976–5983.
   PubMed Web of Science ®Google Scholar
• Fischer M, Oberthuer A, Brors B, Kahlert Y, Skowron M, Voth H, Warnat P, Emestus K, Berthold F. Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome. Clin Cancer Res 2006;12:5118–5128.
   PubMed Web of Science ®Google Scholar
• Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J, Swerts K, Bravo S, Scaruffi P, Tonini GP, De Bernardi B, Noguera R, Piqueras M, Canete A, Castel V, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Michon J, Combaret V, Fischer M, Oberthuer A, Ambros PF, Beiske K, Denard J, Marques B, Rubie H, Kohler J, Potschger U, Ladenstain R, Hogarty MD, McGrady P, London WB, Laureys G, Speleman F, Vandesompele J. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol 2009;10:663–671.
   PubMed Web of Science ®Google Scholar
• Abel F, Dalevi D, Nethander M, Jornsten R, De Preter K, Vermeulen J, Stallings R, Kogner P, Maris J, Nilsson S. A 6-gene signature identifies four molecular subgroups of neuroblastoma. Cancer Cell Int 2011;11:9.
   PubMed Web of Science ®Google Scholar
• Hackett CS, Hodgson JG, Law ME, Fridlyand J, Osoegawa K, de Jong PJ, Nowak NJ, Pinkel D, Albertson DG, Jain A, Jenkins R, Gray JW, Weiss WA. Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors. Cancer Res 2003;63:5266–5273.
   PubMed Web of Science ®Google Scholar
• Cheng AJ, Cheng NC, Ford J, Smith J, Murray JE, Flemming C, Lastowska M, Jackson MS, Mackett CS, Weiss WA, Marshall GM, Kees UR, Norris MD, Haber M. Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma. Eur J Cancer 2007;43:1467–1475.
   PubMed Web of Science ®Google Scholar